Bright Minds Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapeutics for neurological and psychiatric disorders. Bright Minds Biosciences Inc. works on next-generation compounds targeting serotonin receptor pathways, with programs aimed at conditions such as epilepsy, depression, pain, and other central nervous system disorders. The company’s research emphasizes selective small-molecule drug candidates designed to address severe and life-altering diseases with high unmet medical need. Its current business is centered on drug discovery and development, supported by a pipeline of preclinical and clinical programs in neurology and psychiatry. Bright Minds Biosciences Inc. operates as a research-driven biotech platform focused on advancing novel therapeutics from early development toward potential clinical use.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
C$0.00
Net Income (TTM)
-C$25M
▼ -500.0% YoY
Op. Margin
–
ROIC
-25.52%
▲ +4.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-C$25M
▼ -545.8% YoY
Op. Cash Flow (TTM)
-C$25M
▼ -545.8% YoY
Net Debt
-C$83M
Net Cash Position
Cash & Equiv.
C$83M
Continue Research
Peers
Biotechnology · Pick stocks to compare with DRUG
Held by ETFs
DRUG is in 10 US ETFs. The largest of them, with DRUG's weight in each:
iShares Russell 2000 Growth ETFIWO0.03%of the fund
Fidelity Enhanced Small Cap ETFFESM0.01%of the fund
Vanguard Russell 2000 Growth ETFVTWG0.02%of the fund
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC0.05%of the fund
SPDR S&P International Small Cap ETFGWX0.06%of the fund
Bright Minds Biosciences (DRUG) in three numbers
Questions about Bright Minds Biosciences
Is Bright Minds Biosciences a high-quality business?
Bright Minds Biosciences scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$83M, and its weakest is return on capital at -25.5%. The Quality tab shows every check against its target.
Does Bright Minds Biosciences (DRUG) pay a dividend?
No. Bright Minds Biosciences (DRUG) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing DRUG
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.